SCYX Stock Overview
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
+ 2 more risks
My Notes
NewNotes are coming soon
SCYNEXIS, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.68 |
52 Week High | US$5.27 |
52 Week Low | US$1.42 |
Beta | 1.98 |
1 Month Change | 5.66% |
3 Month Change | -24.66% |
1 Year Change | -63.48% |
3 Year Change | -80.00% |
5 Year Change | -90.06% |
Change since IPO | -98.13% |
Recent News & Updates
Recent updates
Scynexis: Uninvestible At This Point, Downgrading To A Sell Rating
Aug 26SCYNEXIS Q2 2022 Earnings Preview
Aug 12FDA accepts Scynexis' application to expand label for vaginal yeast infections treatment
Aug 01SCYNEXIS gains after favorable data for antifungal agent in new indication
Jul 19SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially
Apr 07SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying
Mar 07Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates
Feb 13Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?
Dec 03Scynexis: Leading The Yeast Infection Treatment Industry
Jul 27Scynexis' Brexafemme qualifies for 10 years of exclusivity for vaginal yeast infections
Jun 09FDA approves SCYNEXIS' BREXAFEMME vaginal yeast infections treatment
Jun 02Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?
Apr 13Market Sentiment Around Loss-Making SCYNEXIS, Inc. (NASDAQ:SCYX)
Mar 15Here's What SCYNEXIS, Inc.'s (NASDAQ:SCYX) Shareholder Ownership Structure Looks Like
Feb 01Cantor initiates with Overweight rating for Scynexis and Ardelyx on potential drug approval
Jan 06Trade Alert: The CEO, President & Director Of SCYNEXIS, Inc. (NASDAQ:SCYX), Marco Taglietti, Has Just Spent US$250k Buying 57% More Shares
Dec 28Scynexis shares drop after pricing its equity offering
Dec 17SCYNEXIS, Inc. (NASDAQ:SCYX): Are Analysts Optimistic?
Dec 15Shareholder Returns
SCYX | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -3.4% | -0.5% | 1.7% |
1Y | -63.5% | 4.6% | -9.6% |
Return vs Industry: SCYX underperformed the US Pharmaceuticals industry which returned 4.3% over the past year.
Return vs Market: SCYX underperformed the US Market which returned -8.5% over the past year.
Price Volatility
SCYX volatility | |
---|---|
SCYX Average Weekly Movement | 12.6% |
Pharmaceuticals Industry Average Movement | 11.5% |
Market Average Movement | 6.7% |
10% most volatile stocks in US Market | 17.5% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: SCYX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: SCYX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | 56 | David Angulo | https://www.scynexis.com |
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC).
SCYNEXIS, Inc. Fundamentals Summary
SCYX fundamental statistics | |
---|---|
Market Cap | US$54.86m |
Earnings (TTM) | -US$77.62m |
Revenue (TTM) | US$4.16m |
13.2x
P/S Ratio-0.7x
P/E RatioIs SCYX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SCYX income statement (TTM) | |
---|---|
Revenue | US$4.16m |
Cost of Revenue | US$599.00k |
Gross Profit | US$3.57m |
Other Expenses | US$81.19m |
Earnings | -US$77.62m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -2.38 |
Gross Margin | 85.61% |
Net Profit Margin | -1,864.15% |
Debt/Equity Ratio | 261.2% |
How did SCYX perform over the long term?
See historical performance and comparison